Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND1 | P24385 | 2/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | GCK | P35557 | 8/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14565745 | 0.80 | CCND1 (0.35) | CCND1CCNE1CDK2CDK6ALDH1A1 | |
| SCHEMBL4768241 | 0.77 | CTSK (0.45) | — | |
| SCHEMBL6559756 | 0.76 | TSHR (0.38) | CCND1CCNE1CDK2CDK6ALDH1A1 | |
| SCHEMBL5446827 | 0.75 | PKM (0.55) | ALDH1A1MAPK1GAAHPGDTSHR | |
| SCHEMBL4839973 | 0.73 | CTSK (0.49) | GCK | |
| SCHEMBL6590970 | 0.72 | CTSK (0.41) | ALDH1A1MAPK1GAAUSP2GCK | |
| SCHEMBL7481625 | 0.72 | CTSK (0.39) | CCND1CCNE1CDK2CDK6ALDH1A1 | |
| SCHEMBL5447085 | 0.71 | PKM (0.55) | ALDH1A1GAASMN1; SMN2TSHRNPSR1 | |
| SCHEMBL7428075 | 0.71 | CTSK (0.43) | CCND1CCNE1CDK2CDK6ALDH1A1 | |
| SCHEMBL6557922 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196099-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-27 | — | — | US | claimed |
| US-20040192742-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-09-30 | — | — | US | claimed |
| US-20070135386-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-14 | — | — | US | disclosed |
| US-7196099-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20040192742-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192742-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | CCND1 3198/4885CCNE1 1723/4885CDK2 1118/4885 |
| US-20070135386-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | CTSS, CTSB, CTSE | CCND1 3198/4885CCNE1 1723/4885CDK2 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.